论文部分内容阅读
为探讨甲氰咪呱（ＣＩＭ）对鼠体内ＩＬ２／ＬＡＫ抗肿瘤作用的影响，将Ｂ１６细胞经尾静脉接种于Ｃ５７ＢＬ／６小鼠，第３ｄ分别应用ＤＨａｎｋｓ液、ＣＩＭ（１０ｍｇ／ｍｌ）＋ＣＩＭ（１μｇ／ｍｌ）诱导的脾细胞，ＩＬ２＋ＩＬ２（５００Ｕ／ｍｌ）诱导的ＬＡＫ细胞，ＣＩＭ（１０ｍｇ／ｍｌ）＋ＩＬ２＋ＣＩＭ（１μｇ／ｍｌ）和ＩＬ２（５００Ｕ／ｍｌ）共同诱导的ＬＡＫ细胞，观察鼠肺转移结节和生存期。结果显示，单用ＣＩＭ并不能减少肺转移结节和延长生存期；ＣＩＭ＋ＩＬ２／ＬＡＫ治疗组与ＩＬ２／ＬＡＫ治疗组相比，可减少肺转移结节（Ｐ＜０．０５）和显著延长生存期（Ｐ＜０．０１）。结果表明，ＣＩＭ能够增强ＩＬ２／ＬＡＫ抗肿瘤作用，可用于治疗肿瘤。
To investigate the effect of cimetidine (CIM) on IL 2/LAK antitumor activity in mice, B16 cells were inoculated into C57BL/6 mice via tail vein. On the 3d, D Hanks solution and CIM (10 mg/ml) were used. Ml) + CIM (1 μg/ml) induced spleen cells, IL2+IL2 (500 U/ml) induced LAK cells, CIM (10 mg/ml) + IL2 CIM (1 μg/ml) and IL2 (500 U/ml) ) Co-induced LAK cells were observed in the lungs for metastatic nodules and survival. The results showed that CIM alone could not reduce pulmonary metastasis nodules and prolong survival; CIM+IL 2/LAK treatment group could reduce pulmonary metastasis nodules compared with IL 2/LAK treatment group (P<0.05) and Significantly prolonged survival (P<0.01). The results showed that CIM can enhance the antitumor effect of IL-2/LAK and can be used to treat tumors.